VERAXA Biotech reports in vitro data for its BiTAC-ADC platform

VERAXA Biotech AG (NASDAQ: VRXA) announced it has generated in vitro proof-of-concept data for its BiTAC-ADC technology platform, according to a press release dated June 18, 2026.

The company said the in vitro studies showed that BiTAC-ADCs can discriminate between breast cancer cells and healthy cells, and demonstrated dose-dependent killing of 3D tumor cell spheroids. The BiTAC-ADC approach uses two separate antibodies, each targeting a distinct tumor-associated antigen, to deliver a systemically inactive prodrug and a cell-impermeable proactivator. The company says the individual components are not toxic by design, and cytotoxicity occurs only when both are internalized into the same cancer cell.

VERAXA plans to attend the BIO International Convention in San Diego, Calif., from June 22-25, 2026, to discuss partnering opportunities based on its BiTAC-ADC and BiTAC-TCE platforms.

"While still early in development, the data now available for our BiTAC-ADC platform indicate that our concept of selectively delivering and activating a toxic payload in tumor cells is working," said Christoph Erkel, Ph.D., Vice President Research & Development at VERAXA.

The company also noted that data from its BiTAC-TCE program was presented at the American Association for Cancer Research Annual Meeting in April 2026. VERAXA said the two datasets support what it describes as two distinct product platform technologies applicable across a range of solid tumor indications.

VERAXA completed a listing on Nasdaq earlier in June 2026. The company is based in Zurich, Switzerland, and was founded on research originating at the European Molecular Biology Laboratory.

You May Also Be Interested In

• Correction: Kepler Cheuvreux Upgrades Siemens AG (SIE:GR) (SIEGY) to Hold
• HSBC Downgrades Stellantis NV (STLA:IM) (STLA) to Reduce
• Crusoe in talks to raise $3B in funding - Bloomberg